Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.420-4.510 for the period, compared to the consensus earnings per share estimate of 4.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $51.75 on Thursday. The firm has a 50-day moving average price of $58.79 and a 200-day moving average price of $61.60. The firm has a market capitalization of $2.45 billion, a PE ratio of 13.69, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 12-month low of $49.28 and a 12-month high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. During the same quarter in the previous year, the company posted $1.32 earnings per share. The business’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare will post 4.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PBH. Jefferies Financial Group decreased their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Finally, Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $74.75.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lido Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 5.4% in the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after acquiring an additional 192 shares in the last quarter. Cerity Partners LLC grew its holdings in Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the period. Diversify Advisory Services LLC raised its holdings in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after purchasing an additional 256 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).